LB Pharmaceuticals Inc (NASDAQ: LBRX) announced the initiation of a Phase 2 trial evaluating LB-102 in patients with bipolar depression ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE